No results for ‘’
Aarti Drugs Ltd
₹428.50
(1.95%)
Tue, 22 Sept 2026, 02:43 pm
Health Technology
Pharmaceuticals: Major
24.5KAarti Drugs Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.89 | 7.11 | 4.47 | 2.79 | 4.32 | 6.52 | 5.71 | 3.83 | 5.25 | 20.43 | 16.01 | 16.78 | 14.52 | 16.83 | 8.33 | 23.09 | 19.37 | 18.81 | 23.27 | 18.44 |
| Price to book ratio | 1.18 | 0.73 | 0.55 | 0.36 | 0.82 | 0.95 | 0.70 | 0.84 | 1.27 | 5.12 | 3.08 | 3.43 | 2.62 | 2.78 | 1.81 | 7.09 | 3.83 | 2.62 | 3.11 | 2.27 |
| Price to sales ratio | 0.52 | 0.34 | 0.20 | 0.12 | 0.25 | 0.31 | 0.19 | 0.21 | 0.33 | 1.44 | 0.97 | 1.15 | 0.96 | 0.97 | 0.65 | 3.01 | 1.60 | 1.15 | 1.58 | 1.30 |
| Price to cash flow ratio | 0 | 5.46 | 4.14 | 1.36 | 2.98 | 43.78 | 10.12 | 3.73 | 5.04 | 23.89 | 12.19 | 9.89 | 33.37 | 14.45 | 5.40 | 47.11 | 76.17 | 31.69 | 12.08 | 13.89 |
| Enterprise value | 328Cr | 306Cr | 289Cr | 243Cr | 306Cr | 417Cr | 416Cr | 491Cr | 693Cr | 2023Cr | 1579Cr | 1848Cr | 1737Cr | 2012Cr | 1560Cr | 6816Cr | 4493Cr | 3728Cr | 4544Cr | 3709Cr |
| Enterprise value to EBITDA ratio | 8.78 | 7.35 | 6.41 | 3.76 | 3.68 | 5.96 | 5.58 | 4.07 | 4.73 | 11.84 | 8.94 | 9.51 | 8.52 | 9.44 | 5.82 | 15.35 | 13.33 | 11.83 | 14.20 | 12.94 |
| Debt to equity ratio | 2.16 | 1.99 | 1.95 | 1.56 | 1.29 | 1.64 | 1.69 | 1.54 | 1.51 | 1.45 | 1.35 | 1.20 | 1.20 | 0.93 | 0.60 | 0.38 | 0.52 | 0.51 | 0.44 | 0.45 |
| Return on equity % | 16.30 | 14.64 | 12.98 | 13.59 | 20.73 | 15.35 | 12.72 | 23.56 | 26.52 | 27.64 | 20.65 | 21.60 | 19.24 | 17.97 | 23.65 | 35.81 | 21.03 | 14.92 | 13.86 | 12.69 |
Aarti Drugs Ltd Ratios
The Aarti Drugs Ltd Ratios page provides a complete fundamental analysis of Aarti Drugs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aarti Drugs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Aarti Drugs Ltd (NSE: AARTIDRUGS, BSE: 524348) is currently trading at ₹428.50, with a market capitalization of ₹3909.55Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Aarti Drugs Ltd remains a key stock for fundamental analysis using Aarti Drugs Ltd Ratios.
Aarti Drugs Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Aarti Drugs Ltd P/E ratio currently stands at 18.44, making it one of the most tracked metrics in Aarti Drugs Ltd Ratios.
Historically, the Aarti Drugs Ltd P/E ratio has shown strong fluctuations:
- 2024: 18.44
- 2023: 23.27
- 2022: 18.81
- 2021: 19.37
- 2020: 23.09
The decline in Aarti Drugs Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Aarti Drugs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.27.
Historical P/B trend:
- 2024: 2.27
- 2023: 3.11
- 2022: 2.62
- 2021: 3.83
Aarti Drugs Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Aarti Drugs Ltd P/S ratio currently stands at 1.30, an important part of Aarti Drugs Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.30
- 2023: 1.58
- 2022: 1.15
- 2021: 1.60
A stable or declining Aarti Drugs Ltd P/S ratio indicates cautious market sentiment.
Aarti Drugs Ltd Price to Cash Flow Ratio (P/CF)
The Aarti Drugs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 13.89.
Historical Aarti Drugs Ltd Price to Cash Flow Ratio:
- 2024: 13.89
- 2023: 12.08
- 2022: 31.69
- 2021: 76.17
- 2020: 47.11
The rising Aarti Drugs Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Aarti Drugs Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Aarti Drugs Ltd EV currently stands at ₹3709Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 3709Cr
- 2023: 4544Cr
- 2022: 3728Cr
- 2021: 4493Cr
Aarti Drugs Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Aarti Drugs Ltd EV/EBITDA ratio is currently 12.94, a key metric in Aarti Drugs Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 12.94
- 2023: 14.20
- 2022: 11.83
- 2021: 13.33
Stable Aarti Drugs Ltd EV/EBITDA indicates balanced valuation.
Aarti Drugs Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Aarti Drugs Ltd D/E ratio is currently 0.45, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.45
- 2023: 0.44
- 2022: 0.51
- 2021: 0.52
Aarti Drugs Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Aarti Drugs Ltd ROE currently stands at 12.69%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 12.69
- 2023: 13.86
- 2022: 14.92
- 2021: 21.03
Aarti Drugs Ltd maintains stable profitability levels.
Aarti Drugs Ltd Ratios Analysis Summary
The Aarti Drugs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aarti Drugs Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Aarti Drugs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.